Intocell Inc

287840

Company Profile

  • Business description

    Intocell Inc possesses independent linker platform technology in the ADC (Antibody-Drug Conjugate) field, which is in the spotlight in the anticancer drug market. The company is researching linker technology that conjugates with drugs and drugs for ADC. The business model of the company is to continuously secure sales through platform technology export that allows linker platform technology to be applied to partner companies' antibodies, and technology export of ADC pipelines.

  • Contact

    101 Sinildong-ro
    Daedeok-gu
    Daejeon
    KOR

    T: +82 427160083

    https://www.intocell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

Stocks News & Analysis

stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.
stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,001.4059.900.67%
CAC 407,850.43106.021.37%
DAX 4024,240.82198.920.83%
Dow JONES (US)44,872.39369.950.83%
FTSE 1009,061.4937.680.42%
HKSE25,538.07408.041.62%
NASDAQ20,938.2945.600.22%
Nikkei 22541,171.321,396.403.51%
NZX 50 Index12,794.0639.68-0.31%
S&P 5006,339.3429.720.47%
S&P/ASX 2008,737.2060.000.69%
SSE Composite Index3,582.300.440.01%

Market Movers